Publications by authors named "Gabriel N Hortobagyi"

100Publications

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment.

Front Oncol 2020 22;10:1197. Epub 2020 Jul 22.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.01197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387712PMC
July 2020

Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients.

Oncologist 2020 May 20. Epub 2020 May 20.

Health Services Research Department, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0744DOI Listing
May 2020

Breast Cancer: 45 Years of Research and Progress.

J Clin Oncol 2020 Jul 7;38(21):2454-2462. Epub 2020 Apr 7.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00199DOI Listing
July 2020

Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.

Am J Cancer Res 2020 1;10(2):648-661. Epub 2020 Feb 1.

Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, Center for Molecular Medicine, China Medical University Taichung 404, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061756PMC
February 2020

John Mendelsohn: A visionary scientist, oncologist and leader.

Genes Cancer 2019 ;10(5-6):109-118

Breast Medical Oncology, The University of Texas MD Anderson Cancer, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/genesandcancer.195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872667PMC
January 2019

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.

Clin Cancer Res 2019 12 12;25(24):7388-7395. Epub 2019 Sep 12.

Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0463DOI Listing
December 2019

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.

Cancer Cell 2019 08 18;36(2):168-178.e4. Epub 2019 Jul 18.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.06.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6793936PMC
August 2019

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.

Am J Cancer Res 2019 1;9(3):608-618. Epub 2019 Mar 1.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448061PMC
March 2019

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

N Engl J Med 2019 03;380(13):1226-1234

From the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange (R.S.M.); the SWOG Statistics and Data Management Center (W.E.B., D.L.L.) and Seattle Cancer Care Alliance and University of Washington Medical Center (J.R.G., H.H.L.) - both in Seattle; Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); London Health Sciences Centre and the National Cancer Institute of Canada Clinical Trials Group, London, ON, Canada (T.A.V.); the Cancer Center of Kansas and Wichita National Cancer Institute Community Oncology Research Program (NCORP), Wichita (S.R.D.); Kaiser Permanente NCORP, Portland, OR (N.R.T.); the University of Michigan, Ann Arbor (D.F.H.); the University of Arizona Cancer Center, Tucson (R.B.L.); and the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1811714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885383PMC
March 2019

Leptomeningeal carcinomatosis in patients with breast cancer.

Crit Rev Oncol Hematol 2019 Mar 1;135:85-94. Epub 2019 Feb 1.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428183038
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2019.01.020DOI Listing
March 2019

New and important changes in breast cancer TNM: incorporation of biologic factors into staging.

Expert Rev Anticancer Ther 2019 04 26;19(4):309-318. Epub 2019 Feb 26.

c Department of Surgery , Cedars-Sinai Medical Center and the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1582335DOI Listing
April 2019

Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

J Clin Oncol 2018 Oct 31:JCO1800317. Epub 2018 Oct 31.

Simona F. Shaitelman, Xiudong Lei, Alastair Thompson, Pamela Schlembach, Elizabeth S. Bloom, Isidora Y. Arzu, Gregory Chronowski, Karen Hoffman, George Perkins, Valerie K. Reed, Shalin J. Shah, Michael C. Stauder, Eric A. Strom, Welela Tereffe, Wendy A. Woodward, Diana N. Amaya, Yu Shen, Gabriel N. Hortobagyi, Kelly K. Hunt, and Benjamin D. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Daniel Buchholz and Tomas Dvorak, Orlando Health UF Health Cancer Center, Orlando, FL; Emily Grade, Banner MD Anderson Cancer Center, Gilbert AZ; and Thomas A. Buchholz, Scripps MD Anderson Cancer Center, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286164PMC
October 2018

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

Oncotarget 2018 Sep 28;9(76):34193-34195. Epub 2018 Sep 28.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188130PMC
September 2018

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.

Breast Cancer Res 2018 10 19;20(1):123. Epub 2018 Oct 19.

Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1050-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194611PMC
October 2018

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Invest New Drugs 2018 12 11;36(6):1103-1109. Epub 2018 Oct 11.

Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0672-z
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0672-zDOI Listing
December 2018

Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.

Oncologist 2019 02 8;24(2):178-184. Epub 2018 Oct 8.

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369945PMC
February 2019

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

J Glob Oncol 2018 09 11;4:1-8. Epub 2017 Aug 11.

Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Doug Pyle, American Society of Clinical Oncology, Alexandria, VA; Eduardo L. Cazap, Sociedad Latinoamericana y del Caribe de Oncología Médica, Buenos Aires, Argentina; Nagi S. El Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Boston, MA; Clement Adebayo Adebamowo, Institute of Human Virology, Baltimore, MD; David R. Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA; Julie Vose, University of Nebraska Medical Center, Omaha, NE; Sandra L. Wong, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and Peter Yu, Hartford HealthCare, Hartford, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180769PMC
September 2018

New and Important Changes in the TNM Staging System for Breast Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:457-467

From the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Surgical Oncology and Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Department of Surgery, Division of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201313DOI Listing
May 2018

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.

Oncologist 2018 11 17;23(11):1282-1288. Epub 2018 Aug 17.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291319PMC
November 2018

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.

Ann Surg Oncol 2018 Jul 18;25(7):1783-1785. Epub 2018 Apr 18.

Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-6486-6DOI Listing
July 2018

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Cancer 2018 06 26;124(11):2299-2305. Epub 2018 Mar 26.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31336DOI Listing
June 2018

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Cancer Cell 2018 02;33(2):187-201.e10

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824730PMC
February 2018

Characterization of bone only metastasis patients with respect to tumor subtypes.

NPJ Breast Cancer 2018 25;4. Epub 2018 Jan 25.

3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41523-018-0054-x
Publisher Site
http://dx.doi.org/10.1038/s41523-018-0054-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785511PMC
January 2018

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Invest New Drugs 2018 04 27;36(2):299-306. Epub 2018 Jan 27.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Dan L. Duncan Building, CPB5.3542, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0564-2
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0564-2DOI Listing
April 2018

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply.

JAMA Oncol 2018 04;4(4):586

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.3868DOI Listing
April 2018

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.

Oncotarget 2017 Sep 31;8(41):70481-70495. Epub 2017 Jul 31.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/19719
Publisher Site
http://dx.doi.org/10.18632/oncotarget.19719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642571PMC
September 2017

Ultrasound Molecular Imaging: A Good Start.

J Clin Oncol 2017 07 12;35(19):2101-2102. Epub 2017 May 12.

Gary J. Whitman and Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9997DOI Listing
July 2017

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Breast Cancer Res Treat 2017 Jul 17;164(1):57-67. Epub 2017 Apr 17.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4233-5
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4233-5DOI Listing
July 2017

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Lancet Oncol 2017 04;18(4):e228-e232

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30192-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140765PMC
April 2017

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

CA Cancer J Clin 2017 07 14;67(4):290-303. Epub 2017 Mar 14.

Professor; Co-Director, Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21393DOI Listing
July 2017

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

J Clin Oncol 2017 Apr 30;35(10):1049-1060. Epub 2017 Jan 30.

W. Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Maheshwari Ramineni, Kelly Hunt, Thomas A. Buchholz, Vicente Valero, Aman U. Buzdar, Wei Yang, Abenaa M. Brewster, Stacy Moulder, and Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston; Andrew Walls, Uniformed Services University of the Health Sciences, San Antonio, TX; Mei Liu, The General Hospital of People's Liberation Army, Beijing, China; Alex Bousamra, Allegheny General Hospital, Pittsburgh, PA; Bruno Sinn, Charite-Universitatsmedizin, Berlin, Germany; and Lajos Pusztai and Christos Hatzis, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455352PMC
April 2017

Ribociclib for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2017 01;376(3):289

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1615255DOI Listing
January 2017

Current challenges of metastatic breast cancer.

Cancer Metastasis Rev 2016 12;35(4):495-514

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9636-yDOI Listing
December 2016

Deubiquitination and Stabilization of PD-L1 by CSN5.

Cancer Cell 2016 Dec 17;30(6):925-939. Epub 2016 Nov 17.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171205PMC
December 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.

Breast Cancer Res Treat 2016 06 4;157(2):339-350. Epub 2016 May 4.

The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3815-yDOI Listing
June 2016

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

Cancer Res 2016 Mar 12;76(5):1284-96. Epub 2016 Jan 12.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas. Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical, University, Taichung, Taiwan. Department of Biotechnology, Asia University, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775355PMC
March 2016

AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation.

Cancer Res 2016 Mar 12;76(6):1451-62. Epub 2016 Jan 12.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan. Department of Biotechnology, Asia University, Taichung, Taiwan. Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2016/01/12/0
Web Search
http://cancerres.aacrjournals.org/content/early/2016/01/12/0
Web Search
http://cancerres.aacrjournals.org/content/early/2016/03/03/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-15-1941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794388PMC
March 2016

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Oncologist 2016 Jan 9;21(1):21-7. Epub 2015 Dec 9.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709200PMC
January 2016

The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine.

J Clin Oncol 2016 Jan 17;34(1):76-82. Epub 2015 Nov 17.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Nagi S. El-Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Tanja Cufer, University of Ljubljana and University Clinic Golnik, Golnik, Slovenia; Eduardo Cazap, National Cancer Institute of Argentina, Latin American and Caribbean Society of Medical Oncology, Buenos Aires, Argentina; Roselle de Guzman, St Luke's Medical Center, Quezon City, the Philippines; Nicholas Anthony Othieno-Abinya, University of Nairobi, Nairobi, Kenya; Jose Angel Sanchez, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras; and Doug Pyle, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.7696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320925PMC
January 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.

Mol Cancer Ther 2015 Dec 6;14(12):2687-99. Epub 2015 Oct 6.

Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674309PMC
December 2015

Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.

Eur J Cancer 2015 Nov 3;51(16):2314-20. Epub 2015 Sep 3.

Department of Medicine, Division of Hematology/Oncology, Mount Sinai Beth Israel, 16th Street and 1st Avenue, New York, NY 10003, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.031DOI Listing
November 2015

Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Am J Transl Res 2015 15;7(6):1009-20. Epub 2015 Jun 15.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, Texas 77030 ; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston Houston, Texas 77030 ; Center for Molecular Medicine, and Graduate Institute of Cancer Biology, China Medical University Taichung 404, Taiwan ; Department of Biotechnology, Asia University Taichung 413, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532735PMC
August 2015

Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.

Breast Cancer Res Treat 2015 Sep 14;153(2):417-23. Epub 2015 Aug 14.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1444, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-015-3533
Web Search
http://link.springer.com/10.1007/s10549-015-3533-x
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3533-xDOI Listing
September 2015

Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.

Clin Breast Cancer 2015 Dec 18;15(6):458-66. Epub 2015 Jun 18.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2015.06.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644681PMC
December 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.

Int J Oncol 2015 Jul 12;47(1):262-8. Epub 2015 May 12.

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904111PMC
July 2015

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Oncologist 2015 Jun 6;20(6):593-7. Epub 2015 May 6.

University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, USA; University of Texas Health and Science Center at Houston, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571779PMC
June 2015

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Clin Breast Cancer 2015 Oct 24;15(5):325-31. Epub 2015 Mar 24.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2015.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568133PMC
October 2015

Reply to F.-C. Bidard et al.

J Clin Oncol 2015 May 13;33(14):1623. Epub 2015 Apr 13.

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.5519DOI Listing
May 2015

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.

Neoplasia 2015 Mar;17(3):279-88

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2015.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372651PMC
March 2015